2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLANE-4-METHANOL, (2R,4S)-(±)--

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H14Cl2N2O3
Molecular Weight	329.179
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of 2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLANE-4-METHANOL, (2R,4S)-(±)--

Structure Search

SMILES

OC[C@H]1CO[C@@](CN2C=CN=C2)(O1)C3=CC=C(Cl)C=C3Cl

InChI

InChIKey=VJZJGRMLFMJRGG-FZMZJTMJSA-N

InChI=1S/C14H14Cl2N2O3/c15-10-1-2-12(13(16)5-10)14(8-18-4-3-17-9-18)20-7-11(6-19)21-14/h1-5,9,11,19H,6-8H2/t11-,14-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C14H14Cl2N2O3
Molecular Weight	329.179
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:25:00 GMT 2025` Edited by `admin` on `Tue Apr 01 21:25:00 GMT 2025`
Record UNII	L12GHF7MXQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1,3-DIOXOLANE-4-METHANOL, 2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-, CIS-

Preferred Name

English

2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLANE-4-METHANOL, (2R,4S)-(±)--

Systematic Name

English

REL-(2R,4S)-2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLANE-4-METHANOL

Systematic Name

English

Code System Code Type Description

FDA UNII

L12GHF7MXQ

Created by admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025

PRIMARY

CAS

61397-58-8

Created by admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025

PRIMARY

PUBCHEM

794639

Created by admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025

PRIMARY

ECHA (EC/EINECS)

262-766-4

Created by admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025

PRIMARY

EPA CompTox

DTXSID501126656

Created by admin on Tue Apr 01 21:25:00 GMT 2025 , Edited by admin on Tue Apr 01 21:25:00 GMT 2025

PRIMARY

Related Record Type Details


					R9400W927I

PARENT -> METABOLITE INACTIVE

Comments:

Evidence that CYP3A4 plays a significant role in metabolism of ketoconazole is that co-administration of CYP3A4 inducers, such as phenytoin, carbamazepine, and rifampin, can cause as much as a 50% reduction in levels of ketoconazole.

Qualification:

MAY BE CLINICALLY SIGNIFICANT